Michael R. Bishop, MD, on Aggressive B-Cell NHL: Tisagenlecleucel vs Standard of Care as Second-Line Therapy

December 16, 2021 By The ASCO Post Staff

Michael R. Bishop, MD, of the University of Chicago, discusses insights from findings of the phase III BELINDA study, which may inform the design of future CAR T-cell trials, as well as the use of second-line tisagenlecleucel therapy in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (Abstract LBA-6).

Related Content